^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    JAK inhibitor

    Related drugs:
    3d
    Efficacy and Safety of JAK Inhibitor Combined with IL-17A Inhibitor for Eczematous Psoriasis: A Prospective, Single-Center, Randomized Controlled, Open-Label Trial (ChiCTR2500114598)
    P=N/A, N=30, Not yet recruiting, The First Affiliated Hospital of Army Medical University of the People's Liberation Army of China; The First Affiliated Hospital of Army Medical Unive
    New trial
    3d
    The efficacy and safety of Tofacitinib combined with mycophenolate mofetil versus tofacitinib in patients with glucocorticoid resistant ICIs-related myocarditis: a multicenter, randomized, controlled clinical study (ChiCTR2500114368)
    P=N/A, N=116, Not yet recruiting, Zhongshan Hospital, Fudan University; Zhongshan Hospital, Fudan University
    New trial
    |
    tofacitinib
    3d
    Real-world study of The efficacy and safety of The JAK inhibitor Baricitinib and Ritlecitinib for the treatment of severe alopecia areata (ChiCTR2500114501)
    P=N/A, N=150, Completed, The FIrst Affiliated Hospital, College of Medicine, Zhejiang University; The FIrst Affiliated Hospital, College of Medicine, Zhejiang University
    New trial
    |
    Litfulo (ritlecitinib)
    3d
    A Retrospective Study Comparing Tofacitinib with Antihistamines in the Treatment of Cholinergic Urticaria and Symptomatic Dermographism (ChiCTR2600117340)
    P4, N=20, Not yet recruiting, Dermatology Hospital of Southern Medical University; Dermatology Hospital of Southern Medical University
    New P4 trial
    |
    tofacitinib
    3d
    Effectiveness and Safety of Topical JAK Inhibitor for Non-Segmental Vitiligo: A Multicenter Real-World Study (ChiCTR2500106366)
    P=N/A, N=110, Recruiting, Sun Yat-sen Memorial Hospital, Sun Yat-sen University; Sun Yat-sen Memorial Hospital, Sun Yat-sen University | Not yet recruiting --> Recruiting
    Enrollment open
    4d
    Interferon-Type-I Response and Autophagy Independently Regulate Radiation-Induced HLA-Class-I Molecule Expression in Lung Cancer. (PubMed, Curr Issues Mol Biol)
    The effect of RT (8 and 3 × 8 Gy) on Interferon beta (IFNβ), IFN-stimulated genes (ISGs), and HLA-class-I expression in combination with IFN-type-I-response inhibitors (Ruxolitinib, Tofacitinib, Amlexanox) targeting the JAK and TBK1 was studied with Flow cytometry and RT-PCR. The current study supports the theory that baseline autophagy, RT-induced autophagy blockage, and IFN-type-I response enhancement define the HLA-class-I levels in NSCLC cells. This complex interplay emerges as a promising target for the development of radio-vaccination strategies to enhance the efficacy of radio-immunotherapy.
    Journal • IO biomarker
    |
    ATG7 (Autophagy Related 7) • IFNB1 (Interferon Beta 1) • MAP1LC3A (Microtubule Associated Protein 1 Light Chain 3 Alpha)
    |
    Jakafi (ruxolitinib) • Aphthasol (amlexanox) • tofacitinib
    6d
    RHODOLITE: Registry Platform Myelofibrosis and Anemia (clinicaltrials.gov)
    P=N/A, N=200, Not yet recruiting, iOMEDICO AG | Initiation date: Sep 2025 --> Mar 2026
    Trial initiation date • HEOR
    6d
    KRXeljanzJIA: Korea Xeljanz Post-marketing Surveillance for Juvenile Idiopathic Arthritis (clinicaltrials.gov)
    P=N/A, N=10, Recruiting, Pfizer | N=375 --> 10
    Enrollment change
    |
    tofacitinib
    12d
    MANIFEST-3: A Phase 3 Study of Pelabresib (DAK539) and Ruxolitinib in Myelofibrosis (MF) (clinicaltrials.gov)
    P3, N=460, Not yet recruiting, Novartis Pharmaceuticals
    New P3 trial
    |
    Jakafi (ruxolitinib) • pelabresib (DAK539)
    18d
    TOFAST: Tofacitinib in Adult Patients With Moderate to Severe Ulcerative Colitis (clinicaltrials.gov)
    P=N/A, N=152, Completed, Pfizer | Recruiting --> Completed | N=280 --> 152
    Trial completion • Enrollment change
    |
    tofacitinib
    29d
    A Clinical Trial of TQ05105 Tablets Combined With TQB3909 Tablets in the Treatment of Myelofibrosis (MF) (clinicaltrials.gov)
    P1/2, N=21, Terminated, Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | N=93 --> 21 | Trial completion date: May 2027 --> Dec 2025 | Recruiting --> Terminated | Trial primary completion date: Jun 2026 --> Dec 2025; Per sponsor request. Premature closure was not prompted by any safety or efficacy concerns.
    Enrollment change • Trial completion date • Trial termination • Trial primary completion date
    |
    TQB3909 • rovadicitinib (TQ05105)
    1m
    FRACTION: Fedratinib in Combination With Nivolumab (clinicaltrials.gov)
    P2, N=30, Active, not recruiting, Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | Trial primary completion date: Dec 2025 --> Mar 2026
    Trial primary completion date
    |
    Opdivo (nivolumab) • Inrebic (fedratinib)